Company Overview
Snapshot
Founded in March 2023 by Michal Gilon Ohev-zion and Noam Shomron, Everly Bio operates with 1–10 employees. The company has raised $1.7 million across one funding round, with its product currently in the R&D stage.
Business overview
Everly Bio is a Health Tech & Life Sciences company focused on revolutionizing fertility treatments. The company leverages novel multisystem molecular insights and advanced computational biology to provide decision support in fertility care. By combining noninvasive technology with molecular insights and AI, Everly Bio aims to enable shorter time to pregnancy and increase accessibility to effective solutions for the growing global issue of infertility. Its platform serves both B2C and B2B markets for diagnosis and intervention.
Log in to access full profile ›Company Intelligence Q&A
- What is Everly Bio's primary focus?
- Everly Bio focuses on fertility care, utilizing a molecular platform to provide decision support for infertility treatments.
- When was Everly Bio founded?
- Everly Bio was founded in March 2023.
- Who are the founders of Everly Bio?
- Everly Bio was co-founded by Michal Gilon Ohev-zion and Noam Shomron.
- What is Everly Bio's total funding to date?
- Everly Bio has raised a total of $1.7 million across one funding round. The company's last funding round was a Pre-Seed round for $1.7 million.
- What technology does Everly Bio use?
- Everly Bio combines noninvasive technology with molecular insights and artificial intelligence to develop its diagnostic and intervention platform for fertility.